Breaking News, Collaborations & Alliances

NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes

Collaboration integrates stem-cell-derived islets with targeted immune modulation.

Author Image

By: Charlie Sternberg

Associate Editor

NewcelX Ltd., a clinical-stage company, has entered a strategic collaboration with Eledon Pharmaceuticals Inc., a clinical-stage immunology company, to advance combination strategies integrating NewcelX’s lead program, NCEL-101, with Eledon’s investigational anti-CD40L monoclonal antibody, tegoprubart (AT-1501), with the goal of supporting durable, immune-protected islet replacement and advancing a potential functional cure for Type 1 Diabetes. Eledon’s tegoprubart is a next...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters